# Clinical Course of Hair Thinning Associated With Teriflunomide: Case Series of Patients Who Participated in a Hair Photography Project

Keith R Edwards, Lori Hendin Travis, Annette Okai, Scott Jackson, Lisa Farnett, Steve Cavalier, Darren Stam, Ken Liu

1Multiple Sclerosis Center of Northeastern New York, Latham, NY, USA; 2Phoenix Neurological Associates Ltd, Phoenix, AZ, USA; 3Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, USA; 4Baton Rouge Clinic, Baton Rouge, LA, USA; 5Genzyme, a Sanofi company, Cambridge, MA, USA

## Hair Thinning at Onset and Follow-Up: All Patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, y</th>
<th>Time from first dose to onset, d</th>
<th>Time from onset to follow-up, d</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>49</td>
<td>114</td>
<td>54</td>
</tr>
<tr>
<td>2.</td>
<td>35</td>
<td>111</td>
<td>94</td>
</tr>
<tr>
<td>3.</td>
<td>47</td>
<td>139</td>
<td>186</td>
</tr>
<tr>
<td>4.</td>
<td>60</td>
<td>75</td>
<td>227</td>
</tr>
<tr>
<td>5.</td>
<td>56</td>
<td>170</td>
<td>303</td>
</tr>
<tr>
<td>6.</td>
<td>34</td>
<td>72</td>
<td>547</td>
</tr>
</tbody>
</table>

### Patient 1
- **Onset**
  - Patient-perceived severity: 1/10
  - HCP-perceived severity: Mild
  - Markedly improved
- **Follow-up**
  - Patient did not notice hair loss
  - Neurologist noticed thinning at top of scalp
  - Continued teriflunomide treatment

### Patient 2
- **Onset**
  - Patient-perceived severity: 1
  - HCP-perceived severity: Moderate
  - Somewhat improved
- **Follow-up**
  - Hair felt thinner with less body
  - Continued teriflunomide treatment

### Patient 3
- **Onset**
  - Patient-perceived severity: 2
  - HCP-perceived severity: Mild
  - Mild
- **Follow-up**
  - Patchy hair thinning, especially in front above forehead and where hair parts
  - Continued teriflunomide treatment

### Patient 4
- **Onset**
  - Patient-perceived severity: 3/10
  - HCP-perceived severity: Mild
  - Complete/near complete resolution
- **Follow-up**
  - Patient noticed thinning on top and front at hairline, by feel only
  - Saw hair on clothes, hairbrush, and in the shower
  - Continued teriflunomide treatment

### Patient 5
- **Onset**
  - Patient-perceived severity: 3/10
  - HCP-perceived severity: Moderate
  - Complete/near complete resolution
- **Follow-up**
  - Patient noticed hair did not feel as full
  - Continued teriflunomide treatment

### Patient 6
- **Onset**
  - Patient-perceived severity: 3
  - HCP-perceived severity: Mild
  - Complete/near complete resolution
- **Follow-up**
  - No balding spot, just overall loss of hair
  - Clumps of hair in the drain after shower
  - Patient chose to temporarily discontinue teriflunomide (23 days)
### Hair Thinning at Onset and Follow-Up: All Patients

**Patient 7.**
- **Age, y:** 60
- **Time from first dose to onset, d:** 31
- **Time from onset to follow-up, d:** 237
- **Patient-perceived severity:** 3/10
- **HCP-perceived severity:** Moderate
- Patient reported more hair in the drain after showering and lots of hair in comb
- Continued teriflunomide treatment

**Patient 10.**
- **Age, y:** 63
- **Time from first dose to onset, d:** 94
- **Time from onset to follow-up, d:** 318
- **Patient-perceived severity:** 5/10
- **HCP-perceived severity:** Mild
- Patient noticed hair loss in showers and hair in comb
- Thinner areas on top, front and behind/above ears
- Continued teriflunomide treatment

**Patient 8.**
- **Age, y:** 52
- **Time from first dose to onset, d:** 30
- **Time from onset to follow-up, d:** 332
- **Patient-perceived severity:** 5
- **HCP-perceived severity:** Mild
- Hair fell out on the floor when combing or brushing
- No particular area worse than any other
- Continued teriflunomide treatment

**Patient 11.**
- **Age, y:** 58
- **Time from first dose to onset, d:** 132
- **Time from onset to follow-up, d:** 168
- **Patient-perceived severity:** 5
- **HCP-perceived severity:** Mild
- Prior history of hereditary hair loss
- Patient could remove hair by running fingers through hair; hair on pillow, hairbrush, and in shower
- Continued teriflunomide treatment

**Patient 9.**
- **Age, y:** 78
- **Time from first dose to onset, d:** 79
- **Time from onset to follow-up, d:** 187
- **Patient-perceived severity:** 5
- **HCP-perceived severity:** Mild
- Grewed thin under “Cowlick section” of hair in back
- Noticed hair on seat “is hit”
- HCP recommended temporary discontinuation (13 days)

**Patient 12.**
- **Age, y:** 62
- **Time from first dose to onset, d:** 31
- **Time from onset to follow-up, d:** 305
- **Patient-perceived severity:** 5
- **HCP-perceived severity:** Mild
- Root-to-tip felt thinner to patient
- Hair loss noticed in brush and shower drain, and on clothes
- Continued teriflunomide treatment

---

Presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), April 18–25, 2015, Washington, DC, USA

Funding provided by Genzyme, a Sanofi company
## Hair Thinning at Onset and Follow-Up: All Patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, y</th>
<th>Time from first dose to onset, d</th>
<th>Time from onset to follow-up, d</th>
<th>Onset</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 13.</td>
<td>70</td>
<td>112</td>
<td>244</td>
<td>Patient perceived severity: 5/10</td>
<td>Follow-up: 3/10, markedly improved</td>
</tr>
<tr>
<td>HCP perceived severity: Mild</td>
<td>Mild</td>
<td>Patient reported mild hair loss, with loss of eyebrows and eyelashes</td>
<td>Continued teriflunomide treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 14.</td>
<td>53</td>
<td>61</td>
<td>253</td>
<td>Patient perceived severity: 5</td>
<td>Follow-up: 1, complete/near complete resolution</td>
</tr>
<tr>
<td>HCP perceived severity: Moderate</td>
<td>Mild</td>
<td>Patient noticed more bald scalp around front of head, by hairline</td>
<td>Continued teriflunomide treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 15.</td>
<td>60</td>
<td>31</td>
<td>277</td>
<td>Patient perceived severity: 7</td>
<td>Follow-up: 1, somewhat improved</td>
</tr>
<tr>
<td>HCP perceived severity: Mild</td>
<td>Mild</td>
<td>Hair loss mostly on sides of head</td>
<td>Continued teriflunomide treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 16.</td>
<td>42</td>
<td>56</td>
<td>158</td>
<td>Patient perceived severity: 7</td>
<td>Follow-up: 6, somewhat improved</td>
</tr>
<tr>
<td>HCP perceived severity: Moderate</td>
<td>Mild</td>
<td>Hair loss on sides of head</td>
<td>Continued teriflunomide treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 17.</td>
<td>44</td>
<td>30</td>
<td>338</td>
<td>Patient perceived severity: 7/10</td>
<td>Follow-up: 1/10, complete/near complete resolution</td>
</tr>
<tr>
<td>HCP perceived severity: Moderate</td>
<td>Mild</td>
<td>Subtle hair thinning seen ~1 month after starting teriflunomide treatment</td>
<td>Patient developed diffuse red rash on scalp and chest</td>
<td>Treatment discontinued due to rash</td>
<td></td>
</tr>
<tr>
<td>Patient 18.</td>
<td>31</td>
<td>30</td>
<td>428</td>
<td>Patient perceived severity: 6</td>
<td>Follow-up: 1, complete/near complete resolution</td>
</tr>
<tr>
<td>HCP perceived severity: Mild</td>
<td>Mild</td>
<td>Patient indicated hair loss was severe at top of head</td>
<td>Continued teriflunomide treatment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), April 18–25, 2015, Washington, DC, USA

Funding provided by Genzyme, a Sanofi company
## Hair Thinning at Onset and Follow-Up: All Patients

### Patient 19.

<table>
<thead>
<tr>
<th>Age, y</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from first dose to onset, d</td>
<td>16</td>
</tr>
<tr>
<td>Time from onset to follow-up, d</td>
<td>315</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onset</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-perceived severity</td>
<td>8/10</td>
</tr>
<tr>
<td>HCP-perceived severity</td>
<td>Mild</td>
</tr>
</tbody>
</table>

- Patient noticed strands of hair in her fingers and reported “front is thinner”
- Continued teriflunomide treatment

### Patient 20.

<table>
<thead>
<tr>
<th>Age, y</th>
<th>52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from first dose to onset, d</td>
<td>45</td>
</tr>
<tr>
<td>Time from onset to follow-up, d</td>
<td>228</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onset</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-perceived severity</td>
<td>10/10</td>
</tr>
<tr>
<td>HCP-perceived severity</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

- Patient reported significant hair loss after showering and combing hair
- Continued teriflunomide treatment

### Patient 21.

<table>
<thead>
<tr>
<th>Age, y</th>
<th>38</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from first dose to onset, d</td>
<td>18</td>
</tr>
<tr>
<td>Time from onset to follow-up, d</td>
<td>370</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onset</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-perceived severity</td>
<td>10</td>
</tr>
<tr>
<td>HCP-perceived severity</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

- Patient thought hair thinning was severe and would not put her hair in a ponytail
- Continued teriflunomide treatment